Development of an orally available inhibitor of CLK1 for skipping a mutated dystrophin exon in Duchenne muscular dystrophy

Yukiya Sako1, Kensuke Ninomiya2, Yukiko Okuno3, Masayasu Toyomoto3, Atsushi Nishida3, Yuka Koike1, Kenji Ohe1, Isao Kii4,†, Suguru Yoshida4, Naohiro Hashimoto5, Takamitsu Hosoya4, Masafumi Matsuo3 & Masatoshi Hagiwara1

Duchenne muscular dystrophy (DMD) is a fatal progressive muscle-wasting disease. Various attempts are underway to convert severe DMD to a milder phenotype by modulating the splicing of the dystrophin gene and restoring its expression. In our previous study, we reported TG003, an inhibitor of CDC2-like kinase 1 (CLK1), as a splice-modifying compound for exon-skipping therapy; however, its metabolically unstable feature hinders clinical application. Here, we show an orally available inhibitor of CLK1, named TG693, which promoted the skipping of the endogenous mutated exon 31 in DMD patient-derived cells and increased the production of the functional exon 31-skipped dystrophin protein. Oral administration of TG693 to mice inhibited the phosphorylation of serine/arginine-rich proteins, which are the substrates of CLK1, and modulated pre-mRNA splicing in the skeletal muscle. Thus, TG693 is a splicing modulator for the mutated exon 31 of the dystrophin gene in vivo, possibly possessing therapeutic potential for DMD patients.

Duchenne muscular dystrophy (DMD) is an X-linked inherited neuromuscular disorder that affects approximately 1 out of 3,500 newborn boys, and the most prevalent fatal muscle-wasting disease1–3. It is characterized by progressive muscle deterioration and wasting due to the absence of dystrophin3. Unfortunately, DMD patients usually succumb to cardiac or respiratory failure attributed to muscle dysfunction in their 20s, and no effective cure is currently available. Nonsense mutations or deletions of exons, which cause frame shifts in the dystrophin mRNA and generate premature termination codons (PTCs), usually result in the lack of dystrophin protein and development of the disease.

Current therapeutic attempts to restore dystrophin protein expression include the induction of exon skipping with antisense oligonucleotides (AONs)4–7 or small molecules (TG003)8 and the suppression of nonsense-mediated mRNA decay, which includes the read-through of PTC (e.g. Ataluren)9,10, by chemical compounds. Several AONs have been designed as exon-skipping therapies, in which ribosomes “skip” the mutated exons in pre-mRNA transcripts to produce an in-frame, but truncated, transcript that is translated into a functional dystrophin protein11–13. However, considering their therapeutic cost and delivery efficiency to muscles, small chemical compounds with exon-skipping function are highly anticipated for DMD therapy.

We previously reported on the small molecule TG003 that promotes skipping of dystrophin exon 31 in cells harboring the c.4303G > T mutation8. In the patient's muscle cells, two dystrophin mRNA transcripts of different lengths are detected in nearly equal amounts—one with the premature TAG termination codon in exon 31,
and the other lacking only exon 31. The dystrophin mRNA lacking the 111-bp exon 31 is in-frame to produce an internally deleted, but functional dystrophin protein. The expression of the functional truncated protein is enhanced by TG003 treatment.

Our initial findings showed that TG003 is an inhibitor of CDC-like-kinases (CLKs; CLK1, 2, 4)14, which phosphorylate stretches of alternating serine and arginine residues in serine/arginine-rich (SR) protein family members15,16. CLK-dependent phosphorylation of SR proteins induces their association with transcribed RNAs17–19 to promote or, in some cases, repress splice-site recognition, resulting in alternative splicing20–22. Thus, TG003 modifies mRNA splicing by inhibiting the phosphorylation of SR proteins14,23,24.

Pharmacological efficacy in target tissues is an unavoidable issue for developing therapeutic modalities. While TG003 was effective in modulating CLK activity and mRNA splicing in cellular models of DMD, its metabolic instability hinders its clinical application. In this study, we identified an orally available selective CLK1 inhibitor, TG693, which promoted exon skipping and production of a truncated functional dystrophin protein in immortalized cells derived from a patient with DMD (c.4303G>T) to the same extent as TG003. Additionally, TG693 was metabolically stable and transiently detected in the skeletal muscle at a bioactive level, supporting its therapeutic potential as an orally available drug candidate.

Results

Development of the metabolically stable CLK1 inhibitor TG693. We screened for stable exon-skipping inducers of the mutant DMD exon 31 (c.4303G>T) in our original chemical library and identified the small molecule 5-(4-pyridinyl)-1H-indazole (henceforth referred to as TG693) as an exon-skipping inducer (Fig. 1a). To test the in vivo stability of TG003 and TG693, mice were administered a single subcutaneous injection of either compound and then serum concentrations were monitored by liquid chromatography-mass spectrometry (LC/MS) at serial time points. While only trace amounts of TG003 were detected, the average TG693 serum concentration was 13 μM at 6 h post-injection, indicating that TG693 was more stable than TG003 in the blood plasma (Fig. 1b). Subsequent analysis on CLK1 inhibition with in vitro kinase assays revealed that TG693 inhibited the phosphorylation of a synthetic SRSF1 RS domain peptide with a half-maximal inhibitory concentration (IC50) of 112.6 nM, approximately 10-fold weaker than that of TG003 (IC50 = 13.1 nM) (Fig. 1c). We also examined whether TG693 served as an ATP-competitive inhibitor. Hanes-Woolf plots showed parallel lines with y-intercepts that correspond to TG693 concentration, demonstrating that TG693 competes with ATP for a single site in CLK1-mediated kinase activity in cells. TG693 inhibits CLK1 kinase activity in cells. TG003 administration to cultured cells inhibits the CLK1-mediated phosphorylation of SR proteins, particularly that of SRSF417. To examine the cellular activity of TG693, HeLa cells were treated with increasing concentrations of compounds, and then SR protein phosphorylation was assessed by western blotting with an anti-pan-phospho-SR antibody that recognizes canonical SR protein family members25. Notably, TG693 and TG003 inhibited the phosphorylation of SRSF4 at 5 μM and SRSF6 at 20 μM and 10 μM, respectively (Fig. 2a), confirming that these compounds act via the same biochemical mechanism.

TG693 induces exon-skipping of a DMD splicing reporter. Since TG693 was shown to be a metabolically stable CLK1 inhibitor, we evaluated the dose-dependent effects of TG693 on the skipping of mutant DMD exon 31 (c.4303G>T) with HeLa cells expressing a H492-Dys Ex31m splicing reporter2. Interestingly, the effects of TG693 and TG003 on the exon-skipping were comparable, despite their differences in suppressing CLK1 activity in in vitro kinase assays (Fig. 2b, upper panel); and TG693 had no effect on wild-type transcript splicing even at 30 μM (Fig. 2c). To determine if this activity was specific to exon 31 mutation, we then evaluated the function of TG693 on exon-skipping with the H492-dysEx27m splicing reporter containing a point deletion in exon 27 (c.3613delG (p.Glu1205LysfsX9)) that causes a frameshift-induced premature termination codon. As shown in Supplementary Fig. S1, TG693 induced exon 27-skipping from H492-dysEx27m reporter, similar to that previously observed with TG0035.

CLK1 pre-mRNA splicing is regulated by CLK1 kinase activity14. In this mechanism, abundant CLK1 levels induce SR phosphorylation, resulting in the removal of exon 4 from CLK1 pre-mRNA and nonsense-mediated mRNA decay26,27. In previous reports, administration of TG003 to cultured cells promoted full-length CLK1 expression14,17. Consistently, CLK1 exon 4-skipped transcript expression was attenuated in the presence of 5 μM TG693 (Fig. 2b, middle panel), suggesting that TG693 exhibited a considerable inhibitory effect on CLK1 and concomitant exon-skipping, similar to that of TG0035.

TG693 restored dystrophin expression in patient-derived cells. We previously reported that TG003 restored dystrophin production in patient-derived myotubes4. Therefore, we investigated the effect of TG693 on dystrophin expression in an immortalized cell line derived from a DMD patient with the c.4303G>T mutation, which was by established by the forced expression of constitutively active cyclin-dependent kinase 4, cyclin D1, and telomerase28,29. Notably, TG693 promoted the skipping of mutant exon 31 (Fig. 3a), but did not affect any other exons (Supplementary Fig. S2 and Table S4). Moreover, TG693 was sufficient to increase dystrophin protein expression in a dose-dependent manner with a 130% and 200% increase at 10 and 20 μM, respectively.
Figure 1. TG693 is a metabolically stable CDC2-like kinase 1 (CLK1) inhibitor. (a) TG693 and TG003 chemical structures. (b) Pharmacokinetic profile of TG693 after a single 30 mg kg \(^{-1}\) dose administered by subcutaneous injection in imprinting control region (ICR) mice. Data indicate the mean ± SEM (n = 3). (c) Recombinant CLK1 was incubated with the substrate peptide in the presence of the indicated concentrations of small molecules. Data represent the means ± SD (n = 3). Representative dose-response curves with Hill slopes are shown. (d) TG693 competitive ATP inhibition is shown in Michaelis-Menten (left) and Hanes-Woolf (right) plots. CLK1 kinase activity was measured at the indicated concentrations of TG693 and ATP. Velocity was plotted versus [ATP] and [ATP]/velocity was plotted versus [ATP]. (e) Map of the inhibitory activities of TG693 on a kinase dendrogram. Percent inhibition by 1 μM TG693 was measured for a panel of 313 kinases. Red circles indicate the inhibited kinases and are sized according to percent inhibition. The illustration was reproduced courtesy of Cell Signaling Technology, Inc. (www.cellsignal.com).
Figure 2. **TG693 promotes skipping of mutated exon 31 in HeLa cells in a dose-dependent manner.** (a) SR protein phosphorylation was assessed in HeLa cells treated with TG693 and TG003 for 1 h. Lamin B served as a loading control. Uncropped images have been provided in Supplementary Fig. S4. (b,c) Effect of TG693 on exon 31 skipping with the reporter plasmid. Transfected HeLa cells were incubated in the presence of TG693, TG003, or DMSO vehicle for 24 h. Reporter and endogenous CLK1 splicing was then analyzed by RT-PCR. GAPDH served as a control. The splicing ratios were quantified by intensity analysis and normalized to GAPDH expression. Uncropped images have been provided in Supplementary Figs S5 and S6, respectively. Data represent the means ± SD (n = 3).

Figure 3. **TG693 induces truncated dystrophin protein expression in patient-derived cells.** Immortalized DMD patient-derived cells were treated with increasing concentrations of TG693 for 2 d. (a) Semi-quantitative RT-PCR for dystrophin exon skipping. The uncropped image is provided in Supplementary Fig. S7. Data represent the means ± SD (n = 3). *p < 0.05. (b) Western blotting of dystrophin protein expression in TG693-treated cells using C-terminal-directed antibody. α-Tubulin was used as a loading control. Uncropped images have been provided in Supplementary Fig. S8. Data are representative of three independent experiments.
(Fig. 3b). Thus, these results supported the therapeutic potential for TG693 in DMD patient cells harboring the c.4303G>T mutation in dystrophin exon 31.

Oral administration of TG693 modulated splicing in mouse skeletal muscle. To analyze the in vivo effects of TG693, mice were orally administered TG693 (30 mg kg\(^{-1}\)). Notably, a significant amount of TG693 (>4 μM) was detected in the tibialis anterior (TA) muscle of mice (Fig. 4a), as well as a marked concomitant reduction of SR protein phosphorylation, particularly that of SRSF4 (Fig. 4b). Further analysis of splicing modulation showed that TG693 promoted full-length Clk1 transcript expression in TA, suggesting that treatment suppressed the excision of exon 4 induced by CLK1 activity (Fig. 4c). TG693 was active in other muscle tissues, such as the heart and diaphragm, as well as skeletal muscle (Fig. 4d). We also confirmed that TG693 had no apparent toxicity in rats at up to 100 mg kg\(^{-1}\) per os (Supplementary Fig. S3). No mortalities or gross abnormalities were observed in TG693-treated animals during the experimental period, nor did it affect body weight in mice administrated an overdose of the compound. Thus, these results suggest that TG693 is a useful tool for inhibition of CLK1 activity in vivo per os.

Discussion
We succeeded in identifying a selective ATP-competitive inhibitor of CLK1, named TG693. TG693 is structurally distinct from TG003 (Fig. 1a), but it similarly shows potent CLK1 inhibition as well as dystrophin exon 31 skipping enhancement in cells (Fig. 2a and b), strengthening our original hypothesis that CLK1 can be the molecular target for splicing manipulation.\(^{8,14}\). TG693 restored the dystrophin protein expression in cells harboring a point mutation (c.4303G>T) in exon 31 of the dystrophin gene by inducing exon-skipping (Fig. 3). The c.4303G>T point mutation in exon 31 attenuates exon recognition by disruption and creation of splicing elements such as exonic splicing enhancer and silencer.\(^{8,30,31}\). Thus, mutated exon 31 is targeted by TG693 to suppress exon recognition without altering wild type transcript splicing (Fig. 2c). We also showed that TG693 promotes skipping of a mutated exon 27 in another patient (Supplementary Fig. S1). In vivo mouse experiments revealed that oral TG693 administration decreased SR protein phosphorylation in muscle tissue and modulated the splicing pattern of endogenous Clk1 (Fig. 4). Thus, these results indicated that TG693 could modulate the splicing pattern of the mutated dystrophin gene in the patient by oral administration. This represents a significant advance in drug-induced exon skipping therapy for DMD.

Splicing modulation has drawn increasing attention as a therapeutic strategy for DMD. In 2016, two antisense drugs that modulate splicing were approved by the U.S. Food and Drug Administration (FDA) (e.g. Eteplirsen and Nusinersen), and exon-skipping therapy has become a reality. While AONs offer a specific way to modulate splicing in a therapeutic manner, some hurdles must be overcome for the orally available antisense drugs.\(^{32,33}\). Compared to AONs, small chemical compounds may not be as specific, but more advantageous for the synthesis cost and the oral availability. Thus, splicing modulation with small molecules can become an alternative therapeutic approach in addition to AONs, and can expand applications of splicing modulation therapy.
CLK1 inhibitors have attracted extensive attention in recent years. Notably, TG693 is the first and only CLK1 inhibitor which is orally available and metabolically stable in blood14,35. As such, we believe that the present study will provide a foundation for the continued development of therapies other diseases associated with aberrant CLK1 activity—such as Alzheimer’s and Influenza36,37.

Our results show that TG693 mediated CLK1 inhibition elicits changes in SR protein phosphorylation, particularly that of SRSF4 and SRSF6 (Figs 2a and 4b). SR proteins regulate a multitude of splicing events in the phosphorylation dependent manner31, raising the possibility that reduction of SR proteins phosphorylation may cause off-target splicing alteration. Therefore, we previously checked transcriptional wide effect of TG003, which similarly inhibits phosphorylation of SR proteins as TG693 in vitro (Fig. 2a), and we found that only 0.3% (110/37487)78 of registered alternative splicing events were skipped enhanced by TG003. TG693 is fairly specific in its inhibition profile, showing significant off target effects (>70%) to only 4 of 313 kinases (Fig. 1e). This solidifies the mode-of-action evidence for TG693. Although we confirmed TG693 had no apparent acute toxicity in rats at up to 100 mg kg\(^{-1}\) \textit{per os} (Supplementary Fig. S3), more preclinical studies with other animal models are necessary to consider the clinical application of TG693. We have also started a project to seek next generation CLK1 inhibitors with a pharmaceutical company to improve the efficacy and selectivity of TG693 based on the information written here.

TG693 is a simple compound with indazole and pyridine groups (Fig. 1a) far more metabolically stable than TG003 which is a benzothiazole compound. We believe that TG003 is easily metabolized via \(O\)-demethylation and subsequent sulfate conjugation of the hydroxyl group38 and likely interacts with CLK1 via hydrogen bonds in the ATP-binding pocket39. In the case of TG693, metabolically stable indazole moiety is suspected to form a hydrogen bond with an amino acid residues of CLK140, but structural studies will be necessary to confirm this hypothesis.

Our results suggest that exon-skipping therapy with orally available small molecule has therapeutic potential to genetic diseases caused by disruption/creation of splicing elements, including Duchenne muscular dystrophy. We believe that our approach is potentially applicable to other genetic diseases caused by nonsense or frameshift mutations in the internal coding exons whose length is a multiple of three. On this criteria, we found 6,244 pathogenic mutations in the NIH ClinVar database that may be target candidates for exon-skipping therapy with TG693. Our efforts have focused on expanding application of TG693 to other diseases, addition to the Duchenne muscular dystrophy.

**Methods**

**Materials.** TG693 was synthesized as detailed in the Supporting Information. TG003 was prepared as described previously40. Both compounds were dissolved in dimethylsulfoxide (DMSO) (Hybr-MAXTM, Sigma-Aldrich, St. Louis, MO, USA). Carboxymethyl cellulose sodium salt was obtained from Nacalai Tesque (Kyoto, Japan).

**Antibodies.** The source and catalog numbers of commercially available primary antibodies have been provided in Supplemental Table 2. Mouse monoclonal antibodies against phospho-SR proteins (1H4) and \(\alpha\)-tubulin (DM1A) were purchased from Invitrogen (Carlsbad, CA, USA) and Thermo Fisher Scientific (Yokohama, Japan), respectively. Rabbit polyclonal antibody against dystrophin was obtained from Abcam (Cambridge, UK). Goat polyclonal antibody against Lamin B (M-20) was purchased from Santa Cruz Biotechnology (Santa Cruz, Dallas, TX, USA). HRP-conjugated anti-rabbit, anti-goat IgG, and anti-mouse IgG secondary antibodies were purchased from GE Healthcare Life Sciences (Pittsburgh, PA, USA), Jackson ImmunoResearch (West Grove, PA, USA), and Abcam, respectively.

**In vitro kinase assay.** CLK1 kinase activity was assessed as previously reported14 with minor modifications. The reaction mixture containing serially diluted inhibitors, 10 mM MOPS-KOH (pH 6.3), 10 mM magnesium chloride, 200 uM EDTA, 1 mM ATP, 0.167 uM of [\(\gamma\)-\(\text{32P}\)] ATP, 0.417 uM of synthetic RS peptide, and recombinant GST-tagged human CLK1 (Cat #04–126, Carna Biosciences, Kobe, Japan) was prepared in a final volume of 25 uL. The reaction mixture was incubated at 30 °C for 30 min, and phosphoric acid was added at a final concentration of 5% to stop the reaction. Then, 25 uL of the reaction mixture was dispensed on a P81 phosphocellulose membrane (Cat #20–134, Merck Millipore, Darmstadt, Germany) and washed four times in 5% phosphoric acid. Cherenkov light from the incorporated \(\text{32P}\) was measured using a liquid scintillation counter. The kinase assay conditions, including the incubation period and concentrations of kinases and substrates, were optimized to maintain linearity during incubation. The net radioactivity was determined by subtracting the background count from the reaction mixture without kinases. The IC\(_{50}\) of each compound was calculated by interpolation on a log-concentration-response curve fitted with a four-parameter logistic equation.

**Kinase profiling.** The effect of 1 uM TG693 on 313 kinases (listed in Supplementary Table S2) was examined with immobilized metal ion affinity-based fluorescence polarization (IMAP) assay or off-chip mobility shift assay (MSA) depending on the kinase being examined with an ATP concentration at the K\(_{M}\) or 1 mM. These assays rely on the phosphorylation of small synthetic peptides developed for each kinase, and detect activity by changes in electrophoretic mobility (MSA assay) or by binding of a fluorescently labelled peptide to a large micro-particle and concomitant polarization increases (IMAP assay). Reaction conditions for each kinase are described in Supplementary Table S5. All kinase assays were carried out at Carna Biosciences (Kobe, Japan). The inhibitory map was constructed using Kinome Render41.

**Immobilized metal ion affinity-based fluorescence polarization (IMAP) Assay.** Substrate/ATP/metal (4 \(\times\)) and kinase (2 \(\times\)) solutions were prepared using with assay buffer (20 mM HEPES, 0.01% Tween-20, 2 mM DTT, pH 7.4), and then mixed in 384-well black plates for 1 hour at room temperature. IMAP binding
solution (IMAP Screening Express kit; Molecular Devices, Sunnyvale, CA, USA) was added to each well and incubated for 30 min. The level of kinase activity was then evaluated by fluorescence polarization at 485/530 nm (Ex/Em).

**Off-Chip Mobility Shift Assay (MSA).** Inhibitor (4 ×), substrate/ATP-Metal (4 ×), and kinase (2 ×) solutions were prepared with assay buffer (20 mM HEPES, 0.01% Triton X-100, 2 mM DTT, pH 7.5) and mixed in 384-well plates at room temperature for 1 or 5 h depending on the kinase. Reactions were stopped by the addition of termination buffer (QuickScout Screening Assist MSA; Carna Biosciences). The entire reaction mixture was then applied to a LabChip system (Perkin-Elmer, Waltham, MA, USA) and the product and substrate peptide peaks were separated and quantified, and then heights of product (P) and substrate (S) peptide peaks were calculated. The level of kinase activity was evaluated with the following equation: activity = P/(P + S).

**ATP kinetics assay.** Kinetic reactions were performed with the same method used for *in vitro* kinase assays, except that 0.05–0.4 μCi of [γ-32P] ATP was used. *Km* and *Vmax* values were calculated with a competitive inhibition model in Prism 6 software (GraphPad Software, San Diego, CA, USA).

**Plasmid construction, cell culture, and transfection.** The H492-dys Ex31m, H492-dys Ex31w, and H492-dys Ex27m plasmids were prepared as described previously. HeLa cells were maintained in low-glucose Dulbecco's modified Eagle's medium (Nacalai Tesque) supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 μg/mL streptomycin. Immortalized muscle cells (D4P4) from a DMD patient with the c.4303G > T mutation were established as described previously. Cells were maintained in Dulbecco's modified Eagle's medium (Wako Pure Chemical Industries, Osaka, Japan) supplemented with 20% fetal bovine serum (Gibco, Grand Island, NY, USA), 2% Ultrapure™ G serum substitute (Pall Corp., NY, USA), and 1% antibiotic-antimycotic solution (Gibco). Transfections were carried out using Lipofectamine 2000 (Thermo Fisher Scientific) following the manufacturer's instructions. For reporter assays, TG693 and TG003 were added to the culture medium for 24 h before analysis.

**RNA Isolation and Semiquantitative RT-PCR.** Total RNA was isolated from HeLa cells in 800 μL Sepasol-RNA I Super G (Nacalai Tesque) and then treated with RQ1 RNase-free DNase (Promega, Madison, Wisconsin, USA) according to the manufacturer's protocol. DMD patient-derived cells were lysed in 800 μL Trizol reagent (Thermo Fisher Scientific) and then RNA was isolated with a Direct-zol RNA MiniPrep kit (Zymo Research, Irvine, CA, USA). Tibalislis anterior (TA) muscle homogenates were prepared using a mortar and then RNA was isolated with an RNasy MiniPrep kit (Qiagen, Hilgen, Germany). First-strand cDNA was synthesized using Superscript II reverse transcriptase (Invitrogen) and random hexamers (TakaraBio, Inc., Shiga, Japan). Semi-quantitative RT-PCR was performed with Ex Taq polymerase (Takara Bio, Inc.) with the following cycle conditions: 95 °C for 2 min, followed by 32 cycles (GAPDH) of denaturation at 95 °C for 20 s, annealing at 58 °C for 20 s, and elongation at 72 °C for 1 min, with a final 5 min incubation at 72 °C in a PCR thermal cycler (Bio-Rad Laboratories, Hercules, CA, USA). PCR products were separated by electrophoresis and stained with ethidium bromide. Images were obtained with a ChemiDoc™ MP Imaging System (Bio-Rad) and analyzed with Image Lab software (Bio-Rad). Skipping efficiencies were determined by quantifying the skipped products with a DNA 1000 LabChip Kit on an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Exon skip/inclusion ratios were calculated as the amount of skipped transcript relative to the sum the full-length and skipped transcript. The primers for semi-quantitative RT-PCR were as follows: human CLK1 forward, 5′-ATG AGA CAC TCA AAG AGA ACT TAC TG-3′; human CLK1 reverse, 5′-CTT TAT GAT GGA TGC ACT CCA C-3′; mouse CLK1 forward, 5′-ATG AGA CAT TCA AAG AGA ACT TAC TG-3′; mouse CLK1 reverse, 5′-CAC TTG ATG ATC GAT GCA TTC C-3′; human GAPDH forward, 5′-CCA TCA CCA TCT TCC AGG AGC GAG-3′; human GAPDH reverse, 5′-GTG ATG ATC GAT GCA TTC C-3′; dystrophin forward, 5′-CTT TAT GAT GGA TGC ACT CCA C-3′; dystrophin reverse, 5′-TCC ACA CTC TTC GTT TTC AAT G-3′; DMD splicing reporter forward, 5′-ATT ACT CTC TCA GAA GCT GTG TTG C-3′; and DMD splicing reporter reverse, 5′-AAG TCT CTC ACT TAG CAA CTG GCA G-3′.

**Western blot analysis.** Proteins were extracted from HeLa cells, immortalized DMD cells, and mouse muscle tissue using CellLytic M (Sigma-Aldrich, St. Louis, MO, USA), 1× Cell Lysis Buffer (Cell Signaling Technology, Danvers, MA, USA), and CellLytic MT (Sigma-Aldrich, respectively). All buffers were supplemented with protease and phosphatase inhibitor cocktail (#25955 and #0757461, Nacalai). Protein concentrations were quantified with Protein Assay Reagent (Pierce by Thermo Fisher Scientific). The HeLa cell and mouse tissue lysates were mixed with Sample buffer (#0949914, Nacalai), denatured at 95 °C for 5 min, and then electrophoresed in a 10% SuperSep™ Ace gel (Wako). The lysates of immortalized cells were mixed with NuPAGE LDS Sample buffer (Thermo Scientific Fisher), denatured at 70 °C for 10 min, and then electrophoresed in a 3–8% NuPAGE Novex Tris-Acetate gels (Thermo Scientific Fisher). The samples were then transferred to PVDF membranes (Pall Corporation, Port Washington, NY, USA). Antibody reactions were performed with Can Get Signal™ Immunoreaction Enhancer Solution (Toyobo, Osaka, Japan). Peroxidase activities were visualized with ImmunoStar P LD (Wako) and a ChemiDoc™ MP Imaging System (Bio-Rad).

**Mice and TG693/TG003 administration.** Seven-week-old, male Jcl:TCR mice were obtained from Charles River Laboratories (Shiga, Japan). All procedures were performed in accordance with the US National Institutes of Health Guide for the Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee of Kyoto University Graduate School of Medicine. Mice were subcutaneously injected with 30 mg kg⁻¹ TG693 or TG003 suspended in 5% DMSO, 5% Solutol, 9% Tween-80, and 81% saline. TG693 was also administered orally at a dose of 30 mg kg⁻¹ suspended in 0.5% carboxymethylcellulose.
In vivo pharmacokinetic analysis. TG693 metabolism and tissue bioavailability were assessed in mouse plasma and muscle tissue. To collect plasma, mice were anesthetized with isoflurane (Mylan, Osaka, Japan) at the indicated time point. Whole blood samples were collected, allowed to clot, and then centrifuged to isolate serum. TG693 or TG003 serum levels were analyzed by LC/MS with an Agilent 6420 Q-TOF mass spectrometer (Agilent Technologies) and ZORBAX HILIC Plus (TG693) or ZORBAX Eclipse Plus C18 (TG003) columns (Agilent Technologies). For muscle tissue bioavailability, mice were sacrificed by cervical dislocation and the tibialis anterior (TA) muscles, heart, and diaphragm dissected. TA homogenates were prepared using a Bead Crusher μT-12 shaking machine (Taitec, Kyoto, Japan) in saline and used to assess TG693 levels by LC/MS with a Poroshell 120 PFP (Agilent Technologies).

Statistical analysis. Statistical analysis was performed using Student’s t-tests, except for the comparison of exon-skipping ratio in patient-derived cells analyzed by one-way ANOVA with independent post hoc Tukey’s multiple comparison testing. Results are reported as the means ± SD. Statistical significance was defined as p < 0.05. IC50 values were calculated from data fitted to a four-parameter logistic curve (variable slope) in Prism 6.0 software.

References
1. Duchenne, G. B. The Pathology of Paralysis with Muscular Degeneration (Paralytism Myosclerotique), or Paralysis with Appendicular Atrophy. Br Med J 2, 541–542 (1867).
2. Zellweger, H. & Antonik, A. Newborn screening for Duchenne muscular dystrophy. Pediatrics 55, 30–34 (1975).
3. Hoffman, E. P., Brown, R. H. Jr. & Kunkel, L. M. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51, 919–928 (1987).
4. Matsuo, M. Duchenne/Becker muscular dystrophy: from molecular diagnosis to gene therapy. Brain Dev 18, 167–172 (1996).
5. Wood, M. J., Gait, M. J. & Yin, H. RNA-targeted splice-correction therapy for neuromuscular disease. Brain 133, 957–972 (2010).
6. Aartsa-Rus, A. & van Ommen, G. J. Less is more: therapeutic exon skipping for Duchenne muscular dystrophy. Lancet Neurol 8, 873–875 (2009).
7. Le Roy, F., Charton, K., Lorson, C. L. & Richard, I. RNA-targeting approaches for neuromuscular diseases. Trends Mol Med 15, 580–591 (2009).
8. Nishida, A. et al. Chemical treatment enhances skipping of a mutated exon in the dystrophin gene. Nat Commun 2, 308 (2011).
9. Welch, E. M. et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 447, 87–91 (2007).
10. Malik, V. et al. Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy. Ann Neurol 67, 771–780 (2010).
11. Takeshima, Y. et al. Intravenous infusion of an antisense oligonucleotides results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy. Pedia-tri Res 59, 690–694 (2006).
12. Takeshima, Y., Nishio, H., Sakamoto, H., Nakamura, H. & Matsuo, M. Modulation of in vitro splicing of the upstream intron by modifying an intron-exon sequence which is deleted from the dystrophin gene in dystrophic K562. J Clin Invest 95, 515–520 (1995).
13. Pramono, Z. A. et al. Induction of exon skipping of the dystrophin transcript in lymphoblastoid cells by transfecting an antisense oligodeoxyribonucleotide complementary to an exon recognition sequence. Biochem Biophys Res Comm 226, 445–449 (1996).
14. Muraki, M. et al. Manipulation of alternative splicing by a newly developed inhibitor of CLks. J Biol Chem 279, 24246–24254 (2004).
15. Colwill, K. et al. The Clk/Sty protein kinase phosphorylates SR splicing factors and regulates their intranuclear distribution. EMBO J 15, 265–275 (1996).
16. Johnson, K. W. & Smith, K. A. Molecular cloning of a novel human cdc2/CDC28-like protein kinase. J Biol Chem 266, 3402–3407 (1991).
17. Ninomiya, K., Kataoka, N. & Hagiwara, M. Stress-responsive maturation of CLK1/4 pre-mRNAs promotes phosphorylation of SR splicing factor. The Journal of cell biology 195, 27–40 (2011).
18. Prasad, J. & Manley, J. L. Regulation and substrate specificity of the SR protein kinase Clk/Sty. Mol Cell Biol 23, 4139–4149 (2003).
19. Aubol, B. E. et al. N-terminus of the protein kinase CLK1 induces SR protein hyperphosphorylation. Biochem J 462, 143–152 (2014).
20. Shepard, P. J. & Hertel, K. J. The SR protein family. Genome Biol 10, 242 (2009).
21. Long, J. C. & Caceres, J. F. The SR protein family of splicing factors: master regulators of gene expression. Biochem J 417, 15–27 (2009).
22. Pandit, S. et al. Genome-wide analysis reveals SR protein cooperation and competition in regulated splicing. Mol Cell 50, 223–235 (2013).
23. Yomoda, J. et al. Combination of Clk family kinase and SRp75 modulates alternative splicing of Adenovirus E1A. Genes Cells 13, 233–244 (2008).
24. Sakuma, M., Iida, K. & Hagiwara, M. Deciphering targeting roles of splicing modifier compounds: case of TG003. BMC Mol Biol 16, 16 (2015).
25. Neugebauer, K. M., Stolk, J. A. & Roth, M. B. A conserved epitope on a subset of SR proteins defines a larger family of Pre-mRNA splicing factors. The Journal of cell biology 129, 899–908 (1995).
26. Duncan, P. L., Stojdl, D. F., Marius, R. M., Scheit, K. H. & Bell, J. C. The Clk2 and Clk3 dual-specificity protein kinases regulate the intranuclear distribution of SR proteins and influence pre-mRNA splicing. Exp Cell Res 241, 300–308 (1998).
27. Duncan, P. L., Stojdl, D. F., Marius, R. M. & Bell, J. C. In vivo regulation of alternative pre-mRNA splicing by the Clk1 protein kinase. Mol Cell Biol 17, 5996–6001 (1997).
28. Nishida, A. et al. Staurosporine allows dystrophin expression by skipping of nonsense-encoding exon. Brain Dev 38, 738–745 (2016).
29. Shiomi, K. et al. CDK4 and cyclin D1 allow human myogenic cells to recapture growth property without compromising differentiation potential. Gene Ther 22, 3402–3407 (2015).
30. Zhou, J., Maveda, A. & Krainer, A. R. Exon identity established through differential antagonism between exonic splicing silencer-bound hnrNP A1 and enhancer-bound SR proteins. Mol Cell 8, 1351–1361 (2001).
31. Okumoto, H. I. & Krainer, A. R. Cooperative-binding and splicing-repressive properties of hnrNP A1. Mol Cell Biol 29, 5620–5631 (2009).
32. Havens, M. A. & Hastings, M. L. Splice-switching antisense oligonucleotides as therapeutic drugs. Nucleic Acids Res 44, 6549–6563 (2016).
33. Murakami, M. & Watanabe, C. Can colorable delivery technology provide a platform for enteral oligonucleotide-based therapeutics? Drug Discov Ther 10, 273–275 (2016).
34. Naert, G. et al. Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Abeta25-35 peptide administration in mice. Eur Neuropsychopharmacol 25, 2170–2182 (2015).
35. Bidmos, M. et al. CLK2 inhibition ameliorates autist features associated with SHANK3 deficiency. Science 351, 1199–1203 (2016).
36. Jain, P. et al. Human CDCC2-like kinase 1 (CLK1): a novel target for Alzheimer’s disease. Curr Drug Targets 15, 539–550 (2014).
37. Karlas, A. et al. Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication. *Nature* **463**, 818–822 (2010).
38. Masaki, S. et al. Design and synthesis of a potent inhibitor of class 1 DYRK kinases as a suppressor of adipogenesis. *Bioorg Med Chem* **23**, 4434–4441 (2015).
39. Ogawa, Y. et al. Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A. *Nat Commun* **1**, 86 (2010).
40. Bamborough, P. et al. N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: indazoles as phenol isosteres with improved pharmacokinetics. *Bioorg Med Chem Lett* **17**, 4363–4368 (2007).
41. Chartier, M., Chenard, T., Barker, J. & Najmanovich, R. Kinome Render: a stand-alone and web-accessible tool to annotate the human protein kinome tree. *PeerJ* **1**, e126 (2013).

**Acknowledgements**

We thank the members of the M.H. laboratory for experimental assistance, helpful discussions, and comments. We also acknowledge Dr. Shin’ichi Takeda and the members of his lab, especially Dr. Yoshitsugu Aoki and Dr. Takashi Saito, at the National Center of Neurology and Psychiatry (NCNP) for technical advice. We are grateful to Dr. Kei Iida, Dr. Akihide Takeuchi, Motoyasu Hosokawa, Maki Sakuma, Kohei Araki, and Keiko Hayashi at Kyoto University for their helpful comments and experimental assistance. We also thank the Radioisotope Research Center and Medical Research Support Center at Kyoto University for instrumental support. Illustrations were reproduced courtesy of Cell Signaling Technology, Inc. This study was supported by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (Grant No. 15H05721 to M.H. and 15K10050 to K.O.), the Research Program of Innovative Cell Biology (No. 231006 to M.H.), the National Institute of Biomedical Innovation (NIBIO, No. 241011 to M.H.), and Intramural Research Grant 25-5 for Neurological and Psychiatric Disorder of NCNP (to M.H.).

**Author Contributions**

Y.S., K.N., K.O., I.K., and T.H. designed the study. Y.S. performed experiments and analyzed the data. K.N. performed the compound screening. Y.O. assisted with the ATP kinetics assay. M.T. assisted with the pharmacokinetic assay in mouse skeletal muscle. Y.K. performed the pharmacokinetic assay with mouse whole blood. S.Y. and T.H. synthesized small molecules. N.H. and M.M. generated the immortalized patient-derived cells. A.N. and M.M. constructed of the reporter vector and performed RT-PCR and western blotting. Y.S., K.N., K.O., and I.K. wrote the manuscript. S.Y., T.H., and M.H. provided feedback during manuscript preparation. M.H. supervised the study.

**Additional Information**

Supplementary information accompanies this paper at http://www.nature.com/srep

**Competing Interests:** The authors declare no competing financial interests.

**How to cite this article:** Sako, Y. et al. Development of an orally available inhibitor of CLK1 for skipping a mutated dystrophin exon in Duchenne muscular dystrophy. *Sci. Rep.* **7**, 46126; doi: 10.1038/srep46126 (2017).

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2017